Bartholin gland adenocarcinoma

Summary

Bartholin gland adenocarcinoma (MONDO:0003853) is a disease. A subtype of bartholin gland carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Bartholin gland adenocarcinoma
Mondo ID	MONDO:0003853
DOID	DOID:6316
NCIT	C7719
UMLS	C0238016
MedGen	116035
GARD	0023696
Anatomy (UBERON)	UBERON:0000460
Is cancer (heuristic)	no

Also known as: adenocarcinoma of the Bartholin’s gland · Bartholin gland adenocarcinoma · major vestibular gland adenocarcinoma

Disease family

This is a subtype of bartholin gland carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › bartholin gland carcinoma › Bartholin gland adenocarcinoma

Related subtypes (3): Bartholin gland transitional cell carcinoma, bartholin gland squamous cell carcinoma, Bartholin gland small cell carcinoma

Subtypes (1): Bartholin gland adenoid cystic carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.